Dendritic Cell-Based Vaccine for the Treatment of Malignant Glioma: A Systematic Review

Wang, Xuan; Zhao, Hongyang; Zhang, Fangcheng; Sun, Yun; Zhang, Xiong; Jiang, Xiaobing

doi:10.3109/07357907.2014.958234

Cited by 40 publications

(27 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A particular subset of immunotherapy involves the use of dendritic cells that are pulsed with tumor antigens to elicit an immune response against GBM. When exposed to Because it is identical to vaults normally found in the body, it poses little threat to healthy tissue [71] the proper antigens, these therapeutics facilitate the adaptive immune system to kill tumor cells [10][11][12]. Other therapies utilize interleukin-13 receptor a chain variant 2, which is overexpressed in GBM and is an immunotherapeutic target for monoclonal antibody treatment, dendritic cell treatment, and chimeric antigen receptor-expressing T cell treatment that are under active investigation [13].…”

Section: Immunotherapy For Gbmmentioning

confidence: 98%

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Ung

Yang

2015

J Neurooncol

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is characterized as one of the most common and most deadly malignant primary brain tumors. Current treatment modalities include the use of surgical resection and adjuvant chemotherapy and radiation therapy, though survival is still limited. Because of this, new treatment strategies are needed to improve overall survival. Immunotherapy has emerged as a potential treatment, but still possesses certain limitations to have a substantial clinical effect. In addition, nanotechnology has emerged as potent treatment effectors that have been shown to augment the effects of therapies including chemotherapy, gene therapy, and more. Nanoparticles possess a novel approach due to the myriad of functional groups that can create targeted treatments, though further optimization is still required. In this review, the authors will present the current uses and abilities of nanotechnology and its implication for use with immunotherapy in the treatment of GBM.

show abstract

Section: Immunotherapy For Gbmmentioning

confidence: 98%

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Ung

Yang

2015

J Neurooncol

View full text Add to dashboard Cite

show abstract

“…The typical biological characteristic of this type of malignant tumor is invasive growth, including that into the surrounding healthy brain tissue. Due to the location of such tumors within the brain, it is difficult to remove them using surgery alone, resulting in poor prognosis (5,6). Therefore, the conventional treatment for glioma involves a combination of surgery and chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide‑induced autophagic death of U251 glioma cells

Zhou

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Glioma is a malignant tumor of the glial tissue that is difficult to excise through surgery, with poor patient prognosis. The use of chemotherapeutic drugs alone to treat glioma following surgery results in a high probability of sequelae, such as tumor recurrence. The present study investigated the effects of a novel treatment combination on glioma cells and determined the molecular mechanisms underlying its action. The effect of temozolomide (TMZ) combined with rapamycin (RAPA) on the TMZ-induced autophagic death of U251 glioma cells was examined. The U251 cell line was treated with TMZ combined with RAPA, and the cell survival rate and half maximal inhibitory concentration (IC 50 ) of TMZ/RAPA was detected using the Cell Counting Kit-8 (CCK-8) assay. Flow cytometry was used to detect changes in cell cycle distribution. The formation of acidic vesicular organelles (AVOs) in the cytoplasm was identified using fluorescence microscopy and quantitatively analyzed. Western blotting was performed to detect the expression levels of autophagy-associated proteins Beclin-1 and microtubule associated protein 1 light chain 3 alpha (MAP1LC3A)-I and II. RAPA (1.25 nM) combined with 5 µM TMZ markedly inhibited U251 cell growth. RAPA reinforced TMZ-induced autophagic death, reducing the IC 50 value of treatment when combined (TMZ alone, 22.5±3.23 µM vs. TMZ and RAPA, 10.35±2.81 µM). Compared with the control group, the proportion of cells in G 2 /M were markedly increased following treatment with TMZ combined with RAPA. Acridine orange staining demonstrated that TMZ combined with RAPA could markedly enhance the generation of intracellular AVOs compared with TMZ or RAPA alone. In addition, Beclin-1 and LC3-II protein expression was markedly increased compared with the control and single treatment groups (P<0.05). The results of the present study indicate that RAPA reinforces TMZ-induced autophagic death of U251 glioma cells, providing a novel therapeutic combination for the treatment of malignant glioma.

show abstract

“…Dendritic Cell-Based Cancer Immunotherapy after the demonstration of survival gains in DC-treated cancer patients in a number of trials Cao et al, 2014;Wang et al, 2014). The foremost example is sipuleucel-T (Provenge; Dendreon Corporation, Seattle, WA), the first and currently the only DCbased immunotherapeutic that received approval from the U.S. Food and Drug Administration.…”

Section: Cancer Immunotherapymentioning

confidence: 99%

“…Cell-Based Cancer Immunotherapy: The Acute Myeloid Leukemia Showcase A growing body of evidence indicates that DC vaccination can be of clinical benefit to cancer patients (Draube et al, 2011;Anguille et al, 2014;Cao et al, 2014;Wang et al, 2014), encouraging the further development of this form of immunotherapy. Nevertheless, there is a general agreement among cancer researchers that the true clinical potential of DCbased cancer immunotherapy has not been attained yet (Bot et al, 2013;Datta et al, 2014).…”

Section: Toward the Delivery Of Effective Dendriticmentioning

confidence: 99%

Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy

Anguille¹,

Smits²,

Bryant³

et al. 2015

Pharmacol Rev

136

138

View full text Add to dashboard Cite

Dendritic Cell-Based Vaccine for the Treatment of Malignant Glioma: A Systematic Review

Abstract: Immunotherapy may improve the survival of patients with GBM.

Cited by 40 publications

References 38 publications

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme

Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide‑induced autophagic death of U251 glioma cells

Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy

Contact Info

Product

Resources

About